TOT Biopharm International Co (HKSE:01875) GF Value : HK$28.25 (As of Dec. 13, 2024)

View and export this data going back to 2019. Start your Free Trial

What is TOT Biopharm International Co GF Value?

As of today (2024-12-13), TOT Biopharm International Co's share price is HK$1.75. TOT Biopharm International Co's GF Value is HK$28.25. Therefore, TOT Biopharm International Co's Price-to-GF-Value for today is 0.06. Based on the relationship between the current stock price and the GF Value, GuruFocus believes TOT Biopharm International Co is Possible Value Trap, Think Twice.

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

TOT Biopharm International Co (HKSE:01875) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

TOT Biopharm International Co's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	1.75	/	28.25
	=	0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TOT Biopharm International Co GF Value Related Terms

Thank you for viewing the detailed overview of TOT Biopharm International Co's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

TOT Biopharm International Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TOT Biopharm International Co Ltd (HKSE:01875) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

120 Changyang Street, Suzhou Industrial Park, Suzhou, CHN, 215024

Website

https://www.totbiopharm.com.cn

TOT Biopharm International Co Ltd is a clinical-stage biopharmaceutical company dedicated to developing and commercializing oncology drugs and therapies for patients and their families as well as medical professionals. It has a pipeline of oncology drug candidates, which include monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). It generates revenues from Mainland China.

Executives

Center Laboratories, Inc.	2201 Interest of corporation controlled by you
Tricor Trust (hong Kong) Limited	2301 Trustee
Chengwei Evergreen Capital, Lp	2101 Beneficial owner
Center Laboratories Inc.	2101 Beneficial owner
Chengwei Evergreen Management, Llc	2201 Interest of corporation controlled by you
Suzhou Vivo Management Consulting Partnership (limited Partnership)
Vivo (suzhou) Health Industry Investment Fund (limited Partnership)
Vivo Capital Llc
Vivo Capital Viii, Llc
Vivo Capital Fund Viii, L.p.
Prime Success International Limited	2101 Beneficial owner
Advantech Capital Ii L.p.
Advantech Capital Ii Master Investment Limited
Advantech Capital Investment V Limited
Advantech Capital Partners Ii Limited

TOT Biopharm International Co Headlines

No Headlines